Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Extension in HER2+ Breast Cancer
NCT05910398Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2023
- Primary completion
- Apr 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib in breast cancer, sponsored by Renji Hospital. Started Jun 2023; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05910398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910398.